Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy

Some patients with pulmonary arterial hypertension (PAH) might undergo transition to parenteral prostacyclin analogs due to inadequate response to oral combination therapy. However, there is no consensus on how transition from oral selexipag to subcutaneous treprostinil should be performed. Herein,...

Descripción completa

Detalles Bibliográficos
Autores principales: Adachi, Shiro, Nishiyama, Itsumure, Yasuda, Kenichiro, Yoshida, Masahiro, Nakano, Yoshihisa, Kondo, Takahisa, Murohara, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese College of Cardiology 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214813/
https://www.ncbi.nlm.nih.gov/pubmed/35923524
http://dx.doi.org/10.1016/j.jccase.2022.02.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214813/
https://www.ncbi.nlm.nih.gov/pubmed/35923524
http://dx.doi.org/10.1016/j.jccase.2022.02.003

Ejemplares similares